Skip to main content
SpringerLink
Log in

Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro

  • Original Articles
  • Alkylating Agents, Lonidamine, CDDP, BCNU, 4-HC, l-Phenylalanine Mustard
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

We examined the ability of lonidamine, which has been described as an inhibitor of cellular respiration and glycolysis, to enhance the cytotoxicity of alkylating agents to MCF-7 human breast-carcinoma cells. Lonidamine was increasingly cytotoxic to MCF-7 cells with increasing time of exposure. With a 12-h exposure, the IC50 for lonidamine was about 365 μM, and with a 24-h exposure it was about 170 μM. A drug concentration of 250 μM was chosen for use in the drug combination studies. Lonidamine appeared to have a dose-modifying effect on cisplatin (CDDP), producing increasingly supraadditive cell kill with increasing CDDP concentration. When simultaneously incubated with lonidamine for 1 h, 500 μM CDDP yielded a cell kill that was 2 log greater than additive cytotoxicity. Extending the exposure to lonidamine for 12 h after CDDP treatment led to a small, additional aliquot of cell kill of about 2.5-fold over the CDDP concentration range. Lonidamine also appeared to have a dose-modifying effect on melphalan cytotoxicity in the melphalan concentration range of 100–500 μM. Between concentrations of 10 and 100 μM melphalan, the drug combination survival after 1 h exposure fell within the envelope of additivity for the two agents. However, maintaining the presence of lonidamine for an additional 12 h increased the effect such that the combination was supraadditive over the entire concentration range of melphalan. Simultaneous exposure to 4-hydroperoxycyclophosphamide (4-HC) and lonidamine for 1 h resulted in greater than additive cell kill, and extending the lonidamine exposure period such that lonidamine was present during and 12 h after 4-HC treatment further increased this effect. Lonidamine had a moderate effect on the cytotoxicity of carmustine (BCNU) with a 1 h simultaneous exposure; however, this treatment combination reached greater than additive cytotoxicity only at the highest concentration of BCNU tested. Extending the lonidamine exposure time for an additional 12 h resulted in supraadditive cell kill over the BCNU concentration range. Therefore, when lonidamine was present during exposure to the alkylating agent and its presence was then extended for an additional 12 h, a synergistic cell kill was produced with all four alkylating agents tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Band PR, Deschamps M, Besner JG, Leclaire R, Gervais P, DeSanctis A (1984) Phase II study of lonidamine in cancer patients Oncology 41 [Suppl 1]:66

    Google Scholar 

  2. Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 28:1

    Google Scholar 

  3. Cavaliere R, DiFilippo F, Varanese A, Carlini S, Calabro A, Aloe L, Piarulli L (1984) Lonidamine and hyperthermia: clinical experience in melanoma; preliminary results. Oncology 41 [Suppl]:116

    Google Scholar 

  4. Deen DF, Williams MW (1979) Isobologram analysis of X-ray BCNU interactions in vitro. Radiat Res 79:483

    Google Scholar 

  5. DeMartino C, Battelli T, Paggi MG, Nista A, Marcante ML, D'Atri S, Malorni W, Gallo M, Floridi A (1984) Effects of lonidamine on murine and human tumor cells in vitro. Oncology 41 [Suppl 1]:15

    Google Scholar 

  6. DeMartino C, Malorni W, Accinni L, Rosati F, Nista A, Formisano G, Silvestrini B, Arancia G (1987) Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 46:15

    Google Scholar 

  7. Dewey WC, Stone LE, Miller HH, Giblak RE (1971) Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells X-irradiated during different phases of the cell cycle. Radiat Res 47:672

    Google Scholar 

  8. Evans WK, Shepherd Fa, Mullix B (1984) Phase II evaluation of lonidamine in patients with advanced malignancy. Oncology 41 [Suppl 1]:69

    Google Scholar 

  9. Floridi A, Lehninger AL (1983) Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226:73

    Google Scholar 

  10. Floridi A, Paggi MG, D'Atri S, DeMartino C, Marcante ML, Silvestrini B, Caputo A (1981) Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41:4661

    Google Scholar 

  11. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, DeMartino C (1981) Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:497

    Google Scholar 

  12. Floridi A, Bagnato A, Bianchi C, Paggi MG, Nista A, Silvestrini B, Caputo A (1986) Kinetics of inhibition of mitochondrial respiration by antineoplastic agent lonidamine. J Exp Clin Cancer Res 5:273

    Google Scholar 

  13. Hahn GM, van Kersen I, Silvestrini B (1984) Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50:657

    Google Scholar 

  14. Kim JH, Alfieri A, Kim SH, Young CW, Silvestrini B (1984) Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine. Oncology 41 [Suppl 1]:36

    Google Scholar 

  15. Kim JH, Kim SH, Alfieri A, Young CW, Silvestrini B (1984) Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo. Oncology 41 [Suppl 1]: 30

    Google Scholar 

  16. Kim JH, Alfieri AA, Kim SH, Young CW (1986) Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 46:1120

    Google Scholar 

  17. Magno L, Terraneo F, Ciottoli GB (1984) Lonidamine and radiotherapy in head and neck cancers, a pilot study. Oncology 41 [Suppl 1]:113

    Google Scholar 

  18. Murray N, Shah A, Band P (1987) Phase II study of lonidamine in patients with small cell carcinoma of the lung. Cancer Treat Rep 71:1283

    Google Scholar 

  19. Pacilio G, Carteni G, Biglietto M, DeCesare M (1984) Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients. Oncology 41 [Suppl 1]:108

    Google Scholar 

  20. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85

    Google Scholar 

  21. Teicher BA, Holden SA, Cucchi CA, Cathcart KNS, Korbut TT, Flatow JL, Frei E III (1988) Combination ofN,N 1,N 11-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 48:94

    Google Scholar 

  22. Weinerman BH, Eisenhauer EA, Besner JG, Coppin CM, Stewart D, Band PR (1986) Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70:751

    Google Scholar 

  23. Zupi G, Greco C, Laudonio N, Benassi M, Silverstrini B, Caputo A (1986) In vitro and in vivo potentiation by lonidamine of the antitumor effect of Adriamycin. Anticancer Res 6:1245

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, 44 Binney Street, 02115, Boston, MA, USA

    Kristina W. Rosbe, Terrence W. Brann, Sylvia A. Holden, Beverly A. Teicher & Emil Frei III

Authors
  1. Kristina W. Rosbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terrence W. Brann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia A. Holden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beverly A. Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emil Frei III
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by a grant from DeSanctis Consultants, Montreal, Canada and National Cancer Institute Grant IPOI-CA38493

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosbe, K.W., Brann, T.W., Holden, S.A. et al. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother. Pharmacol. 25, 32–36 (1989). https://doi.org/10.1007/BF00694335

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00694335

Keywords

Search

Navigation